Literature DB >> 3571976

Synergism between eosinophil cationic protein and oxygen metabolites in killing of schistosomula of Schistosoma mansoni.

M Yazdanbakhsh, P C Tai, C J Spry, G J Gleich, D Roos.   

Abstract

To study the cytotoxic reactions responsible for mediating eosinophil damage to schistosomula of Schistosoma mansoni, we have used cytoplasts (eosinophil or neutrophil vesicles devoid of granules and nuclei, with an intact oxidase in their plasma membrane) in combination with purified eosinophil cationic protein (ECP) or major basic protein (MBP) in a cytotoxicity test toward schistosomula. Suboptimal concentrations of ECP (10(-6) M) or MBP (10(-6) M) resulting in less than 10% killing were used in combination with cytoplasts. Cytoplasts alone in the presence of immune serum tested over a wide range of cytoplast:schistosomula ratios generated superoxide and hydrogen peroxide, but were unable to damage schistosomula. However, when a suboptimal ECP concentration (10(-6) M) was combined with neutroplasts or eosinoplasts, 43.9% +/- 8.5 (n = 7) and 24.7% +/- 9.8 (n = 3), respectively, of the schistosomula were killed. Oxygen metabolites were responsible for the synergism, because cytoplasts from a patient with chronic granulomatous disease were unable to act in synergy with ECP. In contrast to ECP, no synergism was found between cytoplasts and MBP (10(-6) to 2 X 10(-5)M). These results show that oxygen metabolites are important for the killing of schistosomula by lowering the concentration of ECP needed to inflict damage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571976

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Phospholipase D-derived phosphatidic acid is involved in the activation of the CD11b/CD18 integrin in human eosinophils.

Authors:  A T Tool; M Blom; D Roos; A J Verhoeven
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

Review 2.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 3.  What is the role of the eosinophil?

Authors:  P Venge
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

4.  Characterization of the phenotype of human eosinophils and their progenitors in the bone marrow of healthy individuals.

Authors:  Marwan Hassani; Selma van Staveren; Erinke van Grinsven; Marije Bartels; Kiki Tesselaar; Guus Leijte; Matthijs Kox; Peter Pickkers; Nienke Vrisekoop; Leo Koenderman
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

5.  Antimicrobial Activity of Human Eosinophil Granule Proteins.

Authors:  Anu Chopra; Janendra K Batra
Journal:  Methods Mol Biol       Date:  2021

Review 6.  The RNase a superfamily: generation of diversity and innate host defense.

Authors:  Kimberly D Dyer; Helene F Rosenberg
Journal:  Mol Divers       Date:  2006-11       Impact factor: 2.943

7.  Effect of oltipraz on the susceptibility of adult Schistosoma mansoni to killing by mouse peritoneal exudate cells.

Authors:  G M Mkoji; J M Smith; R K Prichard
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

8.  Synergism among oxidants, proteinases, phospholipases, microbial hemolysins, cationic proteins, and cytokines.

Authors:  I Ginsburg; R Misgav; A Pinson; J Varani; P A Ward; R Kohen
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

9.  T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment.

Authors:  Kanji Watanabe; Pauline N M Mwinzi; Carla L Black; Erick M O Muok; Diana M S Karanja; W Evan Secor; Daniel G Colley
Journal:  Am J Trop Med Hyg       Date:  2007-10       Impact factor: 2.345

10.  Mapping, phylogenetic and expression analysis of the RNase (RNase A) locus in cattle.

Authors:  Thomas T Wheeler; Nauman J Maqbool; Sandeep K Gupta
Journal:  J Mol Evol       Date:  2012-05-05       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.